drugset / Trial / NCT03654040
Liver Transplantation With Tregs at UCSF
Phase 1/2
Terminated
42 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN) · collabPPD Development, LP · collabRho Federal Systems Division, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
Timeline
- Start
- 2021-04-22
- Primary completion
- 2023-03-06
- Completion
- 2023-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | arTreg | Unknown | 90 cells | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 40 mg/kg | Intravenous |
| Background | Everolimus | Small molecule | — | — |
Indications
No indication recorded.